Business
– Multiple sclerosis treatment Copaxone accounts for an estimated half of Teva’s profit. – Changes in the multiple sclerosis treatment market, in which...
Hi, what are you looking for?
– Multiple sclerosis treatment Copaxone accounts for an estimated half of Teva’s profit. – Changes in the multiple sclerosis treatment market, in which...
– Teva confirmed that it will continue to vigorously defend its Copaxone intellectual property rights. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA)...
– The company is responsible for 10% of the trading turnover on the Tel Aviv 25 Index. /By Gali Weinreb and Tali Tsipori/ ...
– The pharmaceutical firm is seeking a merger at a good premium on its $20 billion market cap. – Sources inform “Globes” that pharmaceutical...
– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that the Company has filed a citizen petition (CP) regarding the approvability of purported generic versions of...
– The activist shareholder still fears that the Teva board won’t do what the company needs. – – “These are definitely steps in the...
– Chaim Hurvitz and Dan Suesskind will step down and Chairman Phillip Frost will leave before the end of the year. – – Chaim...
– Eyal Desheh: There are many small US companies developing complex generic products. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is eying small acquisitions...
– – Last year, Rami Levy joined BTI, the group of businesspeople that supports peace with the Palestinians for the sake of the economy....
– VBL is developing drugs for the treatment of cancer and inflammatory diseases. On Friday, VBL Therapeutics Ltd. (formerly Vascular Biogenics) published a draft prospectus...